HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION

本研究的具体目的是：1)确定大剂量阿昔洛韦与阿糖腺苷治疗是否能进一步降低中枢神经系统或弥散性新生儿HSV感染的急性和长期随访的发病率和死亡率。2)为确定新生儿大剂量阿昔洛韦化疗是否安全且耐受，将监测以下指标：a)宿主功能生化及骨髓参数（SGOT、BUN、肌酐、CBC差异、血小板计数、尿液分析）。b)宿主抗体反应（ELISA检测的HSV总抗体和特异性多肽抗体）c)急性和长期随访的不良反应。3)确定是否对抗病毒药物产生耐药性4)扩大新生儿HSV感染婴儿的疾病分类以预测预后5)确定大剂量阿昔洛韦与vibaridine治疗中病毒排泄模式是否有变化6)确定脑脊液中HSV糖蛋白特异性抗原和抗体是否预测长期神经预后7)确定脑脊液中是否出现特异性抗原和抗体在治疗后晚期，表明病毒在大脑中潜伏地重新激活。

Specific objectives of this study are: 1) To determine whether high-dose acyclovir vs. vidarabine therapy can further decrease morbidity and mortality of CNS or disseminated neonatal HSV infection both acutely and on long-term follow-up. 2) To determine if high dose acyclovir chemotherapy is safe and tolerated in the newborn, the following will be monitored- a) biochemical and bone-marrow parameters of host function (SGOT, BUN, creatinine, CBC with differential, platelet count, and urinalysis). b) host antibody response (total HSV antibodies by ELISA and antibodies to specific polypeptides.) c) Adverse effects both acutely and on long-term follow-up. 3) To determine if resistance to antiviral medication develops 4) To amplify disease classification for babies with neonatal HSV infection for purposes of predicting prognosis 5) To determine whether there is a change in viral excretion patterns in high-dose acyclovir vs. vibaridine therapy 6) To determine whether antigens and antibodies specific for HSV glycoproteins within the CSF predict long-term neurologic outcome 7) To determine whether specific antigens and antibodies in the CSF appear late after treatment and are indicatiove of insidious reactivation of virus in the brain.